Genprex, Inc. (GNPX) Stock Price, News, Quote & History - Yahoo Finance (2024)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},f=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var m=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===m&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NasdaqCM - Delayed Quote • USD

Compare

2.0200 -0.0200 (-0.98%)

At close: June 21 at 4:00 PM EDT

2.0184 -0.00 (-0.08%)

After hours: June 21 at 4:16 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for GNPX

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

• Previous Close 2.0400
• Open 2.0820
• Bid --
• Ask --
• Day's Range 2.0200 - 2.1400
• 52 Week Range 2.0100 - 42.0000
• Volume 32,106
• Avg. Volume 106,801
• Market Cap (intraday) 4.239M
• Beta (5Y Monthly) -0.53
• PE Ratio (TTM) --
• EPS (TTM) -18.8100
• Earnings Date Aug 21, 2024 - Aug 26, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 165.00

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

www.genprex.com

26

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Genprex, Inc.

Recent News: GNPX

View More

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Tender Offer/Acquisition Reports

Offering Registrations

See Also

Genprex Inc (GNPX) Stock Message Board | InvestorsHubGenprex Inc (GNPX) Stock Price & News - Google FinanceGNPX Stock Price and Chart — NASDAQ:GNPX — TradingViewGenprex Inc Stock Price - GNPX | ADVFN

View More

Performance Overview: GNPX

Trailing total returns as of 6/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNPX

78.04%

S&P 500

14.57%

1-Year Return

GNPX

93.69%

S&P 500

24.52%

3-Year Return

GNPX

98.51%

S&P 500

31.16%

5-Year Return

GNPX

96.42%

S&P 500

84.98%

Compare To: GNPX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

GNPXGenprex, Inc.

2.0200

-0.98%

Mkt Cap 4.239M

Industry Biotechnology

CRDFCardiff Oncology, Inc.

2.4500

+0.41%

Mkt Cap 109.606M

Industry Biotechnology

RVPHReviva Pharmaceuticals Holdings, Inc.

1.2500

-7.41%

Mkt Cap 37.272M

Industry Biotechnology

FENCFennec Pharmaceuticals Inc.

6.42

-1.83%

Mkt Cap 176.808M

Industry Biotechnology

ADTXAditxt, Inc.

1.4000

-5.41%

Mkt Cap 2.791M

Industry Biotechnology

ABEOAbeona Therapeutics Inc.

4.5800

See Also

Genprex, Inc. (GNPX) Stock Price, Quote & News - Stock Analysis

+1.33%

Mkt Cap 187.609M

Industry Biotechnology

DAREDaré Bioscience, Inc.

0.4345

+3.04%

Mkt Cap 43.925M

Industry Biotechnology

REPLReplimune Group, Inc.

8.50

+8.01%

Mkt Cap 522.028M

Industry Biotechnology

CYDYCytoDyn Inc.

0.1400

-0.71%

Mkt Cap 148.17M

Industry Biotechnology

CGTXCognition Therapeutics, Inc.

1.9000

-6.86%

Mkt Cap 76.111M

Industry Biotechnology

KALAKALA BIO, Inc.

5.40

0.00%

Mkt Cap 15.209M

Industry Biotechnology

Statistics: GNPX

View More

Valuation Measures

As of 6/21/2024

• Market Cap

  4.24M

• Enterprise Value

  -3.98M

• Trailing P/E

  --

• Forward P/E

  --

• PEG Ratio (5yr expected)

  --

• Price/Sales (ttm)

  --

• Price/Book (mrq)

  0.48

• Enterprise Value/Revenue

  --

• Enterprise Value/EBITDA

  0.18

Financial Highlights

Profitability and Income Statement

• Profit Margin

  0.00%

• Return on Assets (ttm)

  -96.86%

• Return on Equity (ttm)

  -202.83%

• Revenue (ttm)

  --

• Net Income Avi to Common (ttm)

  -27.63M

• Diluted EPS (ttm)

  -18.8100

Balance Sheet and Cash Flow

• Total Cash (mrq)

  8.22M

• Total Debt/Equity (mrq)

  --

• Levered Free Cash Flow (ttm)

  -13.02M

View More

Research Analysis: GNPX

View More

View More

People Also Watch

DARE Daré Bioscience, Inc.

0.4345

+3.04%

CODX Co-Diagnostics, Inc.

1.4700

+1.38%

COCP Cocrystal Pharma, Inc.

2.6600

+4.31%

AIM AIM ImmunoTech Inc.

0.4104

+4.29%

AYTU Aytu BioPharma, Inc.

2.9100

+4.68%

OPGN OpGen, Inc.

2.4100

+2.12%

VTVT vTv Therapeutics Inc.

18.83

-1.21%

AGRX Agile Therapeutics, Inc.

0.3170

0.00%

NNVC NanoViricides, Inc.

1.8200

-10.34%

CTXR Citius Pharmaceuticals, Inc.

0.6090

-4.92%

PIXY ShiftPixy, Inc.

1.8100

-7.65%

CAPR Capricor Therapeutics, Inc.

4.7000

-1.26%

CLSD Clearside Biomedical, Inc.

1.0800

-6.09%

HOTH Hoth Therapeutics, Inc.

0.9240

-0.66%

BSGM BioSig Technologies, Inc.

0.3580

+3.77%

VBIV VBI Vaccines Inc.

0.5980

+2.01%